In situ forming poly(lactic acid-co-glycolic acid) implants containing leuprolide acetate/β-cyclodextrin complexes: preparation, characterization, and in vitro drug release

被引：14

作者：

Rahimi, Mehdi ^{[1
]}

Mobedi, Hamid ^{[2
]}

Behnamghader, Aliasghar ^{[3
]}

机构：

[1] Islamic Azad Univ, Dept Biomed Engn, Sci & Res Branch, Tehran, Iran

[2] Iran Polymer & Petrochem Inst, Dept Novel Drug Delivery Syst, Tehran, Iran

[3] Mat & Energy Res Ctr, Biomat Grp, Tehran, Iran

来源：

INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS | 2016年 / 65卷 / 02期

关键词：

In situy forming implant; PLGA; leuprolide acetate/beta-cyclodextrin complexes; in vitro drug release; POLYMER MOLECULAR-WEIGHT; ETHER-BETA-CYCLODEXTRIN; MICROCLIMATE PH; SUBCUTANEOUS INJECTION; INCLUSION COMPLEXES; CONTROLLED DELIVERY; MICROSPHERES; FORMULATION; SYSTEM; DICLOFENAC;

D O I：

10.1080/00914037.2015.1055633

中图分类号：

TB3 [工程材料学]; R318.08 [生物材料学];

学科分类号：

0805 ; 080501 ; 080502 ;

摘要：

In situ forming implants (ISIs) based on poly(lactic acid-co-glycolic acid) (PLGA) containing leuprolide acetate/beta-cyclodextrin (LA/beta-CD) complexes were prepared. Incorporation of LA or complexes did not change T-g values of ISIs (48.4-49.6 degrees C). ISIs containing complexes with more beta-CD content showed higher surface and bulk porosity. Higher beta-CD portion in complexes improved solvent release, decreased initial burst release and facilitated diffusion out of drug for corresponding ISIs. Complexation of LA with beta-CD (1/10, w/w) significantly improved its stability within PLGA matrix before release (total LA release of 91.3%). Sls did not show any cellular cytotoxic effects against L929 fibroblast cells. [GRAPHICS] .

引用

页码：75 / 84

页数：10

共 51 条

[1] Carbon nanotubes-graft-polyglycerol: Biocompatible hybrid materials for nanomedicine
Adeli, Mohsen
Mirab, Narjes
Alavidjeh, Mohammad Shafiee
Sobhani, Zahra
Atyabi, Fatemeh
[J]. POLYMER, 2009, 50 (15) : 3528 - 3536
[2] Injectable implants for the sustained release of protein and peptide drugs
Agarwal, Priyanka
Rupenthal, Ilva D.
[J]. DRUG DISCOVERY TODAY, 2013, 18 (7-8) : 337 - 349
[3] Astaneh Reyhaneh, 2006, DARU-Journal of Pharmaceutical Sciences, V14, P65
[4] Changes in Morphology of In Situ Forming PLGA Implant Prepared by Different Polymer Molecular Weight and its Effect on Release Behavior
Astaneh, Reyhaneh
Erfan, Mohammad
Moghimi, Hamidreza
Mobedi, Hamid
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (01) : 135 - 145
[5] Cyclodextrins as pharmaccutical solubilizers
Brewster, Marcus E.
Loftsson, Thorsteinn
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) : 645 - 666
[6] Phase inversion dynamics of PLGA solutions related to drug delivery - Part II. The role of solution thermodynamics and bath-side mass transfer
Brodbeck, KJ
DesNoyer, JR
McHugh, AJ
[J]. JOURNAL OF CONTROLLED RELEASE, 1999, 62 (03) : 333 - 344
[7] The utility of cyclodextrins for enhancing oral bioavailability
Carrier, Rebecca L.
Miller, Lee A.
Ahmed, Mran
[J]. JOURNAL OF CONTROLLED RELEASE, 2007, 123 (02) : 78 - 99
[8] Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimer's Disease
Casadesus, Gemma
Zhu, Xiongwei
Atwood, Craig S.
Webber, Kate M.
Perry, George
Bowen, Richard L.
Smith, Mark A.
[J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (04) : 281 - 285
[9] Subcutaneous Injection of Diclofenac for the Treatment of Pain Following Minor Orthopedic Surgery (DIRECT study): A Randomized Trial
Chiarello, Eugenio
Bernasconi, Stefano
Gugliotta, Barbara
Giannini, Sandro
[J]. PAIN PRACTICE, 2015, 15 (01) : 31 - 39
[10] Terfenadine-β-cyclodextrin inclusion complex with antihistaminic activity enhancement
Choi, HG
Lee, BJ
Han, JH
Lee, MK
Park, KM
Yong, CS
Rhee, JD
Kim, YB
Kim, CK
[J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (08) : 857 - 862

← 1 2 3 4 5 6 →